Nervonik Raises $52.5M in Series B Funding

The company plans to use the funds to continue developing and commercializing its PNS system, including improving its proprietary sensing technology.

The company’s technology uses real-time body signals to personalize and enhance treatment effectiveness. Early results show it can successfully record ECAPs and other biomarkers using implantable leads, placing Nervonik at the forefront of next-generation bioelectronic medicine.

"Nervonik is building a fundamentally differentiated neuromodulation platform that integrates stimulation with advanced sensing to deliver more precise and personalized therapy," said Aydin Babakhani, CEO and Founder of Nervonik. "This financing enables us to accelerate our clinical programs, prepare for commercialization and bring a truly intelligent, next-generation therapy to the patients who need it most."

Read More:Fathom Therapeutics Raises $47M in Series A Funding

"Peripheral nerve stimulation is at an inflection point, with expanding clinical evidence and growing adoption in the treatment of chronic pain," said Anthony Natale, MD, Partner at Amzak Health. "Aydin and the Nervonik team have developed a highly differentiated technology platform that we believe has the potential to improve the patient experience meaningfully, and they are exceptionally well-positioned to capitalize on this opportunity. We are excited to lead this financing and to support the company through its next phase of growth."

About Nervonik

Founded by Aydin Babakhani, and based in Los Angeles, California, Nervonik, Inc. is a medical device company that develops neuromodulation technologies. Its platform combines stimulation, and sensing to deliver more precise treatments for chronic pain and other neurological conditions.

Read More:Avoca Closes Series B Funding, at $1 Billion Valuation